24 325

Cited 10 times in

Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy.

Authors
Kwon, HC; Cheong, JY; Cho, SW; Choi, JM; Hong, SP; Kim, SO; Yoo, WD
Citation
Journal of gastroenterology and hepatology, 24(1):49-54, 2009
Journal Title
Journal of gastroenterology and hepatology
ISSN
0815-93191440-1746
Abstract
BACKGROUND: To evaluate the effect of reversion to YMDD wild-type on emergence of adefovir (ADV)-resistant mutation and antiviral activity of ADV in lamivudine (LAM)- resistant patients. METHODS: We determined YMDD mutations and ADV-resistant mutations before and every 3 months during ADV monotherapy in 33 LAM-resistant patients using the restriction fragment mass polymorphism (RFMP) method. RESULTS: Reversion to pure YMDD wild-type hepatitis B virus (HBV) occurred in 6% (2/33), 9% (3/33), 20% (4/20) and 35% (6/17) of patients after 12, 24, 36 and 48 weeks, respectively. Five (29%) patients were found to have pure YMDD mutants at 48 weeks of therapy. Among 33 patients, 4 (12%) patients developed ADV-resistant mutations at 48 weeks of therapy. Adefovir-resistant mutants emerged in all patients after reversion to YMDD wild-type HBV. The mean serum HBV reductions, evaluated at 24 weeks of therapy, were not different between patients with and without reversion to YMDD wild-type HBV (-3.1 log(10) copies/mL vs-3.4 log(10) copies/mL, P > 0.05). CONCLUSIONS: ADV-resistant mutations emerged after reversion to YMDD wild-type in LAM-resistant patients who received ADV monotherapy. Thus, ADV add-on therapy may be necessary to reduce the incidence of developing ADV resistance in patients with LAM resistance.
MeSH terms
Adenine/analogs & derivatives*Adenine/therapeutic useAdultAntiviral Agents/therapeutic use*DNA, Viral/bloodDrug Resistance, Multiple, Viral/genetics*FemaleHepatitis B/diagnosisHepatitis B/drug therapy*Hepatitis B virus/genetics*HumansLamivudine/therapeutic use*MaleMiddle AgedMutation*Phosphonic Acids/therapeutic use*Polymorphism, Restriction Fragment LengthSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTime FactorsTreatment OutcomeViral Load
DOI
10.1111/j.1440-1746.2008.05570.x
PMID
19196395
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
정재연조성원
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse